Ieq Capital LLC Makes New Investment in DaVita Inc. $DVA

Ieq Capital LLC purchased a new stake in shares of DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,510 shares of the company’s stock, valued at approximately $7,900,000. Ieq Capital LLC owned 0.06% of DaVita as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Callan Family Office LLC purchased a new position in shares of DaVita in the second quarter worth about $376,000. Allworth Financial LP purchased a new stake in DaVita during the 2nd quarter valued at about $357,000. Vise Technologies Inc. bought a new position in DaVita during the 2nd quarter worth approximately $548,000. E Fund Management Co. Ltd. bought a new position in DaVita during the 2nd quarter worth approximately $364,000. Finally, MSH Capital Advisors LLC purchased a new position in DaVita in the 2nd quarter worth approximately $236,000. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of NYSE DVA opened at $174.21 on Monday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The stock has a market capitalization of $11.11 billion, a P/E ratio of 14.26, a P/E/G ratio of 0.58 and a beta of 0.88. The company’s 50-day moving average is $214.96 and its 200 day moving average is $182.03.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on DVA shares. UBS Group boosted their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Barclays lifted their target price on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Truist Financial dropped their price target on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Finally, Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $221.75.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.